Search
Cancer Clinical Trials in Miami, FL
A listing of 186 Cancer clinical trials in Miami, FL actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
121 - 132 of 186
The city of Miami, Florida, currently has 186 active clinical trials seeking participants for Cancer research studies.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Earn $50 for helping advance breast cancer research
Recruiting
We are looking for women 18+ with a current or past breast cancer diagnosis who are willing to securely connect their breast cancer-related medical records to a research registry. Participants receive a $50 Visa gift card once their diagnosis is verified through their medical records.
Primary eligibility:
• Current or previous breast cancer diagnosis
• Age 18+
• U.S.-based health portal
• Willing to connect medical records related to their breast cancer diagnosis/treatment
• Must maintain the records connection for at least 6 months
Find out if you qualify today.
Primary eligibility:
• Current or previous breast cancer diagnosis
• Age 18+
• U.S.-based health portal
• Willing to connect medical records related to their breast cancer diagnosis/treatment
• Must maintain the records connection for at least 6 months
Find out if you qualify today.
Conditions:
Breast Cancer
Breast Carcinoma
Breast Neoplasms
Metastatic Breast Cancer
Invasive Breast Carcinoma
Featured Therapy
Unique Treatment for High Blood Pressure
Worried about high blood pressure? Think beyond typical high blood pressure treatments.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
Conditions:
High Blood Pressure
High Blood Pressure (& [Essential Hypertension])
High Blood Pressure (Hypertension).
Hypertension
Essential Hypertension
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Offer
Discover Affordable Semaglutide Providers
We Checked the Checkout Page on Every Semaglutide Provider. Here's What We Found.
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
Conditions:
Weight Loss
Morbid Obesity
Featured Offer
On Medicare? GLP-1's Covered By Medicare Part D [Found Partnership]
Found is now serving individuals who are 65-75 with GLP-1 support for weight care. You need Medicare Part D, must be 18 or older, and must meet BMI criteria when you start GLP-1 therapy:
- BMI 35 or higher, or
- BMI 30–34.99 with at least one qualifying condition (diastolic heart failure, uncontrolled hypertension, CKD stage 3a or higher, prediabetes, prior heart attack or stroke, symptomatic peripheral artery disease), or
- BMI 27–29.99 with prediabetes, prior heart attack/stroke, or symptomatic peripheral artery disease.
- BMI 35 or higher, or
- BMI 30–34.99 with at least one qualifying condition (diastolic heart failure, uncontrolled hypertension, CKD stage 3a or higher, prediabetes, prior heart attack or stroke, symptomatic peripheral artery disease), or
- BMI 27–29.99 with prediabetes, prior heart attack/stroke, or symptomatic peripheral artery disease.
Conditions:
Healthy
Overweight
Overweight and Obesity
Obesity
Overweight or Obesity
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
Recruiting
This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as a biomarker to measure response or progression of brain metastasis after SRS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Miami Cancer Institute, Miami, Florida
Conditions: Brain Metastases, Brain Metastases, Adult, Brain Cancer
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
Recruiting
The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with breast cancer who require radiotherapy to the breast/chest wall and regional lymph nodes.
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
05/14/2025
Locations: Miami Cancer Institute, Miami, Florida
Conditions: Breast Cancer
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
Recruiting
This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: University of Miami (Data Collection Only), Miami, Florida
Conditions: Endometrial Cancer, Endometrioid Adenocarcinoma, Endometrial Cancer Stage I
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Recruiting
This study is being done to answer the following question:
Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to the usual treatment when radiotherapy is given to both sides of the neck?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Conditions: Oropharyngeal Cancer
Avatrombopag vs. Placebo for CIT in GI Malignancies
Recruiting
The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy.
The names of the study drugs involved in this study are:
* Avatrombopag (a thrombopoietin receptor agonist)
* Matching placebo
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida
Conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
Recruiting
This research study is being done to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta, or trastuzumab biosimilar) in metastatic HER2+ breast cancer.
The names of the study drugs used in this research study are:
* Sacituzumab govitecan (a type of antibody-drug conjugate)
* Trastuzumab (Herceptin) (a type of monoclonal antibody)
* Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) (a type of recombinant monoclonal antibody)
* Trast... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Miami Cancer Institute at Baptist Health, Miami, Florida
Conditions: Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic
PromotinG Lung Cancer screenIng Awareness and Implementation in Hispanics/Latinx Head and Neck canceR Survivors
Recruiting
The purpose of this study is to assess the awareness of eligibility of lung cancer screening in Hispanic/LatinX Head and Neck Cancer (HNC) survivors using a survey questionnaire; and to understand the barriers to screening using qualitative interviews.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/25/2025
Locations: University of Miami, Miami, Florida
Conditions: Head and Neck Cancer
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Recruiting
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: University of Miami, Miami, Florida
Conditions: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
Metabolic Impact and Compliance of Controlled, Varying, Mediterranean Diets in Pre-Surgical Prostate Cancer Populations (PROVISIONS)
Recruiting
The study aims to investigate whether following a controlled Mediterranean-style diet prior to robotic-assisted radical prostatectomy surgery in patients diagnosed with prostate cancer affects fasting insulin levels and other values that can be measured in blood and tissue samples from surgery.
Gender:
MALE
Ages:
Between 18 years and 80 years
Trial Updated:
04/25/2025
Locations: University of Miami, Miami, Florida
Conditions: Prostate Cancer
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Recruiting
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Clinical Study Site, Miami, Florida
Conditions: Non-Small Cell Lung Cancer
With Love, Grandma ("Con Cariño, Abuelita") Pilot Study
Recruiting
The purpose of this study is to assess the feasibility, acceptability, and preliminary effects of a digital (web and mobile-phone-based) program to improve lifestyle behaviors (physical activity, dietary intake) among Hispanic female cancer survivors and adult daughters.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
04/18/2025
Locations: University of Miami, Miami, Florida
Conditions: Cancer, Breast, Cancer, Uterus, Cancer, Ovary, Obesity, Activity, Motor, Diet, Healthy
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Recruiting
The study purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: University of Miami Hospital and Clinics, Miami, Florida
Conditions: Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
121 - 132 of 186
